The Centers for Disease Control and Prevention (CDC) this week told clinicians that they should “closely monitor” asymptomatic patients who received injections of contaminated steroid products from New England Compounding Center.
However, the CDC does not recommend treating patients with antifungal agents if they show no symptoms of meningitis. The CDC said the data does not suggest an added benefit to treating asymptomatic patients, and that many such patients could experience serious side effects if treated.
The CDC noted that patients’ greatest risk of developing fungal meningitis is during the 42-day time period following an epidural or paraspinal injection from one of the contaminated lots. (The lot numbers are listed below). The CDC said additional monitoring of this group of patients should be considered.
Patients who received such injections more than 42 days ago should still be monitored, the CDC said, with a “low threshold” for performing a lumbar puncture should the patient become symptomatic.
Officials say there is still no evidence that any of the contaminated lots were distributed to any Massachusetts facility, and there have been no illnesses in Massachusetts from the contaminated lots.
New England Compounding Center Lot Numbers
- Methylprednisolone Acetate (PF) 80 mg/ml Injection, Lot #05212012@68, BUD 11/17/2012
- Methylprednisolone Acetate (PF) 80 mg/ml Injection, Lot #06292012@26, BUD 12/26/2012
- Methylprednisolone Acetate (PF) 80 mg/ml Injection, Lot #08102012@51, BUD 2/6/2013